Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405371 | 0.87 | MET (0.56) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3409205 | 0.84 | DYRK1A (0.67) | NPC1RAB9ASMN1; SMN2PIK3CAPIK3CG | |
| SCHEMBL1829706 | 0.83 | DYRK1A (0.51) | NPC1RAB9ASMN1; SMN2PIK3CGDYRK1A | |
| SCHEMBL6068126 | 0.82 | DYRK1A (0.71) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL2799672 | 0.82 | ABL1 (0.60) | ABL1 | |
| SCHEMBL3404307 | 0.81 | MET (0.54) | ABL1 | |
| SCHEMBL12280295 | 0.81 | CASP2 (0.59) | NPC1RAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL612873 | 0.81 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL6067997 | 0.79 | DYRK1A (0.71) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL14189671 | 0.79 | ABL1 (0.70) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091227-B2 | Benzothiazole derivatives | ABBOTT GMBH & CO. KG (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | ABL1 7/4885NPC1 3594/4885RAB9A 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.